Real World Treatment Patterns, Adverse Events and Healthcare Resource Utilization and Costs Among Chronic Lymphocytic Leukemia (CLL) Patients in the United States

Conclusions: The most common regimen during LOT1 was bendamustine + rituximab, and was ibrutinib during LOT2 and LOT3.This study provides evidence that occurrence of AEs among patients with CLL receiving systemic anti-cancer therapy in the real-world setting is substantial and associated with significant health care cost. The economic burden associated with increased AEs underscores the need for treatments with fewer AEs.Figure.DisclosuresKabadi: AstraZeneca: Employment. Le: Optum: Employment; Optum/United Health Group: Equity Ownership. Dacosta Byfield: Optum/United Health Group: Equity Ownership; Optum: Employment. Olufade: AstraZeneca: Employment; AstraZeneca: Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Kabadi, S., Le, L., Dacosta Byfield, S., Olufade, T. O. Tags: 904. Outcomes Research-Malignant Conditions: Real World Outcomes Source Type: research